NCT03283137View on ClinicalTrials.gov

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
CLLB-cell Non Hodgkin Lymphoma
Interventions
DRUG

TGR-1202

TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.

DRUG

Pembrolizumab

Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

60637

University of Chicago, Chicago

06520

Yale University, New Haven

All Listed Sponsors
lead

University of Chicago

OTHER